Immunomodulation Effect of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Continuous Renal Replacement Therapy

Not Applicable

Completed

• Conditions: Acute Kidney Injury
• Interventions: Procedure: Continuous renal replacement therapy with regional citrate anticoagulation; Procedure: Continuous renal replacement therapy with no anticoagulation or heparin

• Registration Number: NCT02423642
• Lead Sponsor: Chulalongkorn University

Brief Summary

The purpose of this study is to study the effect of anticoagulation in immune response with Acute Kidney Injury (AKI) undergoing Continuous Renal Replacement Therapy (CRRT).

Detailed Description

Not available

Study Timeline

• Study Start: 2013-07
• Primary Completion: 2014-11
• Study Completion: 2014-11
• Study First Submitted: 2015-03-31
• Study First Submitted QC: 2015-04-19
• Study First Posted: 2015-04-22
• Status Verified: 2021-03
• Last Update Submitted: 2021-03-03
• Last Update Posted: 2021-03-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Systemic inflammatory response syndrome; SIRS > or = 2 meets definition
• Patients with acute kidney injury in the intensive care ward.
• Requiring continuous renal replacement therapy.

Exclusion Criteria

• Pregnancy
• Cirrhosis
• End stage renal disease
• HIV infection
• Serum creatinine in male > 2 mg/dl and female > 1.5 mg/dl
• Bleeding

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AKI requring CRRT and use regional citrate anticoagulation	Continuous renal replacement therapy with regional citrate anticoagulation	CRRT use regional citrate anticoagulation
AKI requring CRRT and not use regional citrate anticoagulation	Continuous renal replacement therapy with no anticoagulation or heparin	CRRT not use regional citrate anticoagulation

Primary Outcome Measures

Name	Time	Method
Regulation of inflammatory reactions and and opsonization in microorganisms	24 hours	C3a and C5a
Activity of acute phase protein during acute inflammation	24 hours	PAI-1
Functions of inflammatory cells	24 hours	CD11b expression on PMN and HLA-DR expression on monocyte

Secondary Outcome Measures

Name	Time	Method
length of ICU stay	28 days
survival rate	28 days

Trial Locations

Locations (1)

Sasipha Tachaboon; 🇹🇭 Bangkok, Pathumwan, Thailand